Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C

BACKGROUND: Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome MET-based resistance to EGFR-TKIs. OBJECTIVE: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoh, Kiyotaka, Hirashima, Tomonori, Saka, Hideo, Kurata, Takayasu, Ohe, Yuichiro, Hida, Toyoaki, Mellemgaard, Anders, Verheijen, Remy B., Ou, Xiaoling, Ahmed, Ghada F., Hayama, Manabu, Sugibayashi, Ko, Oxnard, Geoffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105224/
https://www.ncbi.nlm.nih.gov/pubmed/33939068
http://dx.doi.org/10.1007/s11523-021-00806-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105224/
https://www.ncbi.nlm.nih.gov/pubmed/33939068
http://dx.doi.org/10.1007/s11523-021-00806-5

Ejemplares similares